Search
Alclometasone
go.drugbank.com/drugs/DB00240ApprovedAlclometasone is synthetic glucocorticoid steroid for topical use in dermatology as anti-inflammatory, antipruritic, antiallergic, antiproliferative and vasoconstrictive agent.
Categories: Corticosteroids, Moderately Potent (Group II)Deferasirox
go.drugbank.com/drugs/DB01609ApprovedInvestigationalDeferasirox is an iron chelator and the first oral medication FDA approved for chronic iron overload in patients receiving long term blood transfusions.
Categories: Compounds used in a research, industrial, or household settingCalfactant
go.drugbank.com/drugs/DB06415ApprovedInvestigationalIt adsorbs to the air:fluid interface in the lungs and works to reduce surface tension, in a manner similar to endogenous pulmonary surfactant. … Calfactant is a sterile, non-pyrogenic lung surfactant intended for intratracheal instillation.
Synonyms: SF-RI 1Maralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigationalwith Alagille syndrome:[L43547] it was granted marketing authorization in Europe on 13 December 2022. … [A239249] No clinical trials have been performed to assess the efficacy of these treatments for cholestatic pruritus and treatments were given based on a prescriber's clinical experience.
Ubrogepant
go.drugbank.com/drugs/DB15328ApprovedInvestigational[A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular … [A189195] The development of oral gepants, including ubrogepant, may therefore constitute a significant advance in migraine headache treatment and may become the new standard of therapy in the treatment
Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesSelegiline
go.drugbank.com/drugs/DB01037ApprovedInvestigationalVet approvedA selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. … It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability.
Categories: Compounds used in a research, industrial, or household setting, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesSynonyms: L-DeprenalinPefloxacin
go.drugbank.com/drugs/DB00487ApprovedA synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.
Categories: Topoisomerase II InhibitorsMF101
go.drugbank.com/drugs/DB05052InvestigationalMF101 is a novel estrogen receptor beta (ERβ) selective agonist and unlike currently available hormone therapies, does not activate the estrogen receptor alpha (ERα), known to be implicated in tumor formation … MF101 is an oral drug designed for the treatment of hot flashes and night sweats in peri-menopausal and menopausal women.
Abrocitinib
go.drugbank.com/drugs/DB14973ApprovedInvestigational[L39774] The Janus kinase (JAK)–signal transducer and activator of transcription (STAT) signalling pathway plays a central role in the pathogenesis of a variety of autoimmune and inflammatory diseases, … [L39784] On January 14, 2022, the FDA approved abrocitinib for the treatment of refractory, moderate-to-severe AD in adults whose disease is not adequately controlled with other systemic drug products,
Aprocitentan
go.drugbank.com/drugs/DB15059ApprovedInvestigational[L50261] It was the first antihypertensive employing a novel mechanism to be approved in almost 40 years.[L50261] … Aprocitentan is a dual antagonist of endothelin receptors A and B used for treatment-resistant hypertension. It is the active metabolite of [macitentan].